These findings demonstrate Glo1 as a key regulator of GSC biology and highlight its potential as a therapeutic target for GSC-directed intervention in GBM. Targeting Glo1 may offer a novel strategy to impair GSC-driven tumor progression and improve GBM treatment outcomes.
Choi et al. (Sat,) studied this question.